Search - tctmd.com

Displaying 761 - 780 of 785

Sort: Relevancy | Date

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

FDA: Global Recall for Roadrunner UniGlide Wire Guides After Coating Contaminated

Michael O'Riordan

August 17, 2016

News Daily News

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Michael O'Riordan

August 16, 2016

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Michael O'Riordan

June 29, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Daily News

止泻药洛哌丁胺的滥用与严重心脏事件包括死亡相关

Michael O'Riordan

June 08, 2016

News Daily News

Serious Cardiac Events, Including Death, Linked to Abuse of Antidiarrheal Medication Loperamide

Michael O'Riordan

June 08, 2016

News Daily News

Los Episodios Cardíacos Serios, incluida la Muerte se asocian a un Abuso del Fármaco Antidiarréico Lorepamida

Michael O'Riordan

June 08, 2016

News Daily News

Abbott Buys St. Jude Medical for $25 Billion, Gaining More Muscle in Cardiovascular Device Arena

Michael O'Riordan

April 29, 2016

News Daily News

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Michael O'Riordan

March 08, 2016

News Daily News

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Michael O'Riordan

March 08, 2016

News Daily News

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Michael O'Riordan

March 08, 2016

News Daily News

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Michael O'Riordan

March 02, 2016

Advertisement

The Bioresorbable Stent Story So Far: What Promise? What Price?

FDA: Global Recall for Roadrunner UniGlide Wire Guides After Coating Contaminated

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

止泻药洛哌丁胺的滥用与严重心脏事件包括死亡相关

Serious Cardiac Events, Including Death, Linked to Abuse of Antidiarrheal Medication Loperamide

Los Episodios Cardíacos Serios, incluida la Muerte se asocian a un Abuso del Fármaco Antidiarréico Lorepamida

Abbott Buys St. Jude Medical for $25 Billion, Gaining More Muscle in Cardiovascular Device Arena

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content